AGIO241220P22500
- 1.60
- 0.000.00%
Agios Pharmaceuticals Newsroom
Here's Why Agios Stock Plummeted More Than 20% on Monday
Scotiabank Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $75
RBC Raises Price Target on Agios Pharmaceuticals to $57 From $55, Keeps Outperform Rating
Small U.S. Stocks Decrease; Agios Pharmaceuticals Posts Biggest Loss
Agios Pharmaceuticals Down Nearly 22%, on Pace for Record Percent Decrease -- Data Talk
Agios Pharmaceuticals Is Maintained at Sector Outperform by Scotiabank
Agios Pharmaceuticals Analyst Ratings
Sector Update: Health Care Stocks Edge Higher Pre-Bell Monday
Agios Reports Results From Late-stage Study of Its Thalassemia Treatment
Scotiabank Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Raises Target Price to $75
Express News | Agios Pharmaceuticals Inc : Scotiabank Raises Target Price to $75 From $53
Agios Pharmaceuticals Meets Phase 3 Primary, Secondary Goals
Agios Presents Results From Phase 3 ENERGIZE-T Study of Mitapivat
Express News | Agios Pharmaceuticals - Filed Regulatory Applications for Mitapivat US, EU, Saudi Arabia ,UAE
Agios Presents Positive Results From Phase 3 ENERGIZE-T Study of Mitapivat at ASH 2024 and Provides Regulatory Update on Mitapivat
Express News | Agios Presents Positive Results From Phase 3 Energize-T Study of Mitapivat at Ash 2024 and Provides Regulatory Update on Mitapivat
High Quality 'SMID-cap' Stocks With Cyclical Exposure – MS
Leerink Partners Maintains Agios Pharmaceuticals(AGIO.US) With Hold Rating
Express News | Agios Pharmaceuticals Announced It Will Present New Data And Results From Its Phase 3 Study On AG-946 At The 66th American Society Of Hematology Annual Meeting In San Diego, California From December 7-10, 2024
Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition